Best practices recommendations in the application of immunohistochemistry in the prostate: Report from the International Society of Urologic Pathology Consensus Conference

American Journal of Surgical Pathology

Volumn 38, Issue 8, 2014, Pages

  Epstein, Jonathan I ^a   Egevad, Lars ^b   Humphrey, Peter A ^c   Montironi, Rodolfo ^d   Amin, Mahul B ^e   Ulbright, Thomas M ^e   Grignon, David ^e   Trpkov, Kiril ^e   Lopez Beltran, Antonio ^e   Zhou, Ming ^e   Argani, Pedram ^e   Delahunt, Brett ^e   Berney, Daniel M ^e   Srigley, John R ^e   Tickoo, Satish K ^e   Reuter, Victor E ^e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e NONE

Author keywords

atypical small acinar proliferation; best practices; immunohistochemistry; ISUP recommendations; p63; prostate; prostatic sarcoma; racemase; small cell carcinomametastatic carcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CONSENSUS DEVELOPMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; STANDARD; UROLOGY;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UROLOGY;

EID: 84904503978     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000238     Document Type: Article

References (140)

1. Goldstein NS, Underhill J, Roszka J, et al. Cytokeratin 34 beta E-12 immunoreactivity in benign prostatic acini. Quantitation, pattern assessment, and electron microscopic study. Am J Clin Pathol. 1999;112:69-74.
2. Brawer MK, Peehl DM, Stamey TA, et al. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45:3663-3667.
3. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.AmJ Surg Pathol. 1989;13:389-396.
4. O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol. 1990;417:191-196.
5. Shah IA, Schlageter MO, Stinnett P, et al. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod Pathol. 1991; 4:220-224.
6. Wojno KJ, Epstein JI. The utility of basal cell-specific anticytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol. 1995;19:251-260.
7. Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cellspecific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168.
8. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002;15:1302-1308.
9. Parsons JK, Gage WR, Nelson WG, et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58:619-624.
10. Sailer V, Stephan C, Wernert N, et al. Comparison of p40 (DeltaNp63) and p63 expression in prostate tissues-which one is the superior diagnostic marker for basal cells? Histopathology. 2013;63:50-56.
11. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002;41:35-41.
12. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662-1670.
13. Shah RB, Kunju LP, Shen R, et al. Usefulness of basal cell cocktail (34betaE12+p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004;122:517-523.
14. Zhou M, Shah R, Shen R, et al. Basal cell cocktail (34betaE12+ p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003;27:365-371.
15. Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol. 2012;43:313-324.
16. Osunkoya AO, Hansel DE, Sun X, et al. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008;32:461-467.
17. Giannico GA, Ross HM, Lotan T, et al. Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study. Am J Surg Pathol. 2013;37:1401-1406.
18. Zhou M, Chinnaiyan AM, Kleer CG, et al. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26: 926-931.
19. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62: 2220-2226.
20. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
21. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174.
22. Jiang Z, Wu CL, Woda BA, et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004;45:218-225.
23. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596.
24. Magi-Galluzzi C, Luo J, Isaacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol. 2003;27:1128-1133.
25. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27: 772-778.
26. Kunju LP, Rubin MA, Chinnaiyan AM, et al. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol. 2003; 120:737-745.
27. Jiang Z, Iczkowski KA, Woda BA, et al. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol. 2004;121:99-107.
28. Zhou M, Aydin H, Kanane H, et al. How often does alphamethylacyl- CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol. 2004;28:239-243.
29. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl- CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology. 2005;47:587-596.
30. Molinie V, Fromont G, Sibony M, et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17:1180-1190.
31. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29:579-587.
32. Sanderson SO, Sebo TJ, Murphy LM, et al. An analysis of the p63/ alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol. 2004;121:220-225.
33. Browne TJ, Hirsch MS, Brodsky G, et al. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004; 35:1462-1468.
34. Jiang Z, Li C, Fischer A, et al. Using an AMACR (P504S)/ 34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005; 123:231-236.
35. Hameed O, Humphrey PA. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol. 2005;124:708-715.
36. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol. 2011;35:608-614.
37. Green WM, Hicks JL, De Marzo A, et al. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate. Hum Pathol. 2013;44:1895-1901.
38. Cheng L, Davidson DD, Maclennan GT, et al. Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion. Am J Surg Pathol. 2013;37:1550-1554.
39. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012;136:935-946.
40. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35: 1062-1068.
41. Minner S, Gartner M, Freudenthaler F, et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol. 2013;26:106-116.
42. Mertz KD, Horcic M, Hailemariam S, et al. Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer. Hum Pathol. 2014;44:2727-2735.
43. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15: 4706-4711.
44. Shah RB, Tadros Y, Brummell B, et al. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and alphamethylacyl- CoA-racemase markers. Hum Pathol. 2013;44:786-794.
45. Pollen JJ, Dreilinger A. Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. Urology. 1984;23:303-304.
46. Nowels K, Kent E, Rinsho K, et al. Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis. Arch Pathol Lab Med. 1988;112:734-737.
47. Golz R, Schubert GE. Prostatic specific antigen: immunoreactivity in urachal remnants. J Urol. 1989;141:1480-1482.
48. Kamoshida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol. 1990;21:1108-1111.
49. Sobin LH, Hjermstad BM, Sesterhenn IA, et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer. 1986;58:136-138.
50. Spencer JR, Brodin AG, Ignatoff JM. Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts. J Urol. 1990;143:122-125.
51. van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol. 1993;17:410-414.
52. Svanholm H. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase. Acta Pathol Microbiol Immunol Scand. 1986;94:7-12.
53. Ellis DW, Leffers S, Davies JS, et al. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol. 1984;81:279-284.
54. Ford TF, Butcher DN, Masters JR, et al. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br J Urol. 1985;57:50-55.
55. Downes MR, Torlakovic EE, Aldaoud N, et al. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. J Clin Pathol. 2013;66: 779-786.
56. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255.
57. Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109:1716-1726.
58. Varma M, Morgan M, Amin MB, et al. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology. 2003;42:167-172.
59. Parwani AV, Kronz JD, Genega EM, et al. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol. 2004;28:651-657.
60. Huang HY, Shariat SF, Sun TT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol. 2007;38:1703-1713.
61. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
62. Moll R, Wu XR, Lin JH, et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147:1383-1397.
63. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
64. Ohtsuka Y, Kawakami S, Fujii Y, et al. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006; 97:1322-1326.
65. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434-1441.
66. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol. 1998;110:385-390.
67. Esheba GE, Longacre TA, Atkins KA, et al. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009;33:347-353.
68. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
69. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.
70. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13-22.
71. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. AmJ Surg Pathol. 2012;36:1472-1476.
72. Genega EM, Hutchinson B, Reuter VE, et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
73. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140.
74. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991;67:2165-2172.
75. Epstein JI, Kuhajda FP, Lieberman PH. Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum Pathol. 1986;17:939-942.
76. Lane Z, Hansel DE, Epstein JI. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol. 2008;32:1322-1326.
77. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-477.
78. Torenbeek R, Lagendijk JH, Van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology. 1998;32:20-27.
79. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostatespecific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50:472-483.
80. Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol. 2005;18: 1217-1222.
81. Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25: 1380-1387.
82. Herawi M, De Marzo AM, Kristiansen G, et al. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol. 2007;38:72-78.
83. Loy TS, Quesenberry JT, Sharp SC. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol. 1992;98:175-179.
84. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32:65-71.
85. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006; 30:705-712.
86. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238-242.
87. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223.
88. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147:935-937.
89. Rubenstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol. 1997;20:376-380.
90. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621-3630.
91. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072-3080.
92. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
93. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011; 24:820-828.
94. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083-1093.
95. Guo CC, Dancer JY, Wang Y, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011;42:11-17.
96. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24:1120-1127.
97. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology. 2010;56: 937-943.
98. Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2- ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol. 2013;44:2227-2233.
99. Slater D. Carcinoid tumour of the prostate associated with inappropriate ACTH secretion. Br J Urol. 1985;57:591-592.
100. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas. Anticancer Res. 1997;17:2343-2346.
101. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-586.
102. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010; 34:1097-1105.
103. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35:432-441.
104. Sheridan T, Herawi M, Epstein JI, et al. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol. 2007;31:1351-1355.
105. Tazawa K, Kurihara Y, Kamoshida S, et al. Localization of prostate-specific antigen-like immunoreactivity in human salivary gland and salivary gland tumors. Pathol Int. 1999;49:500-505.
106. Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol. 2007;2:41.
107. Humphrey PA. Table 14.17. Prostate Pathology. Chicago: ASCP Press; 2003;285.
108. Paterson RF, Gleave ME, Jones EC, et al. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol. 1999;3:277-286.
109. Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy. Arch Pathol Lab Med. 1997;121:724-729.
110. Chuang AY, Epstein JI. Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma. Am J Surg Pathol. 2007;31:1225-1230.
111. Cheville JC, Dundore PA, Nascimento AG, et al. Leiomyosarcoma of the prostate. Report of 23 cases. Cancer. 1995;76:1422-1427.
112. Westfall DE, Folpe AL, Paner GP, et al. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. Am J Surg Pathol. 2009;33:99-105.
113. Jo VY, Fletcher CD. P63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol. 2011;136:762-766.
114. Hansel DE, Herawi M, Montgomery E, et al. Spindle cell lesions of the adult prostate. Mod Pathol. 2007;20:148-158.
115. Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1998;22:148-162.
116. Herawi M, Epstein JI. Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2006;30:694-704.
117. Bostwick DG, Hossain D, Qian J, et al. Phyllodes tumor of the prostate: long-term followup study of 23 cases. J Urol. 2004;172:894-899.
118. Dundore PA, Cheville JC, Nascimento AG, et al. Carcinosarcoma of the prostate. Report of 21 cases. Cancer. 1995;76:1035-1042.
119. Osunkoya AO, Netto GJ, Epstein JI. Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum Pathol. 2007;38: 1836-1841.
120. Owens CL, Epstein JI, Netto GJ. Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry. Arch Pathol Lab Med. 2007;131:599-603.
121. Contreras HR, Ledezma RA, Vergara J, et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelialmesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol. 2010;28:534-540.
122. Fiorentino M, Zadra G, Palescandolo E, et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008;88:1340-1348.
123. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of Ecadherin and beta-catenin in human prostate cancer. Urol Oncol. 2005;23:402-406.
124. Lazari P, Poulias H, Gakiopoulou H, et al. Differential immunohistochemical expression of CD44s, E-cadherin and beta-catenin among hyperplastic and neoplastic lesions of the prostate gland. Urol Int. 2013;90:109-116.
125. Whitaker HC, Girling J, Warren AY, et al. Alterations in betacatenin expression and localization in prostate cancer. Prostate. 2008;68:1196-1205.
126. Aslan G, Irer B, Tuna B, et al. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract. 2006;202:93-98.
127. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156:1511-1516.
128. Bauer JJ, Sesterhenn IA, Mostofi KF, et al. P53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res. 1995;1:1295-1300.
129. Bethel CR, Faith D, Li X, et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 2006;66:10683-10690.
130. Brewster SF, Oxley JD, TrivellaM, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999;161:1238-1243.
131. Cheng L, Pisansky TM, Sebo TJ, et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999;5:2820-2823.
132. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21:1156-1167.
133. Gurel B, Iwata T, Koh CM, et al. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol. 2008;15:319-331.
134. Kuczyk MA, Serth J, Bokemeyer C, et al. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer. 1998;34:679-686.
135. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011;17:6563-6573.
136. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 1996;120:159-166; discussion 166-167.
137. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15:4799-4805.
138. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998;82:168-175.
139. Theodorescu D, Broder SR, Boyd JC, et al. P53, Bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997;158:131-137.
140. Vis AN, van Rhijn BW, Noordzij MA, et al. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002;197:148-154.